Method comparability as prerequisite for biomarker selection ¿ feasibility study

• Unité de recherche: INNOSUISSE
• Numéro de projet: 12040.1;5 PFLS-LS
• Titre du projet anglais: Method comparability as prerequisite for biomarker selection ¿ feasibility study

Description succincte (Allemand)

Method comparability as prerequisite for biomarker selection - feasibility study

Description succincte (Anglais)

Method comparability as prerequisite for biomarker selection ¿ feasibility study

Résumé des résultats (Abstract) (Allemand)

Together FHNW and ProteoMediX will translate verified research results to a clinically applicable diagnostic prototype test for the more accurate detection of prostate cancer addressing a clear unmet medical need. The final test will be based on a unique signature of protein analytes. This proposal comprises a feasibility study using an innovative biosensor-based approach to bridge the gap between mass spectrometrybased verification and immunoassay-based validation of promising diagnostic markers selected from a bundle of candidates, i.e. protein analytes. This feasibility study is key for entering full development aimed at bringing out ProteoMediX¿s first promising product with prognosticated peak sales of 20 million CHF per year.

Résumé des résultats (Abstract) (Anglais)

Together FHNW and ProteoMediX will translate verified research results to a clinically applicable diagnostic prototype test for the more accurate detection of prostate cancer addressing a clear unmet medical need. The final test will be based on a unique signature of protein analytes. This proposal comprises a feasibility study using an innovative biosensor-based approach to bridge the gap between mass spectrometrybased verification and immunoassay-based validation of promising diagnostic markers selected from a bundle of candidates, i.e. protein analytes. This feasibility study is key for entering full development aimed at bringing out ProteoMediX¿s first promising product with prognosticated peak sales of 20 million CHF per year.